Big Pharma Split Corp Class A (PRM) — Cash Flow Reinvestment Rate

Latest as of September 2023: 0.00x

Big Pharma Split Corp Class A (PRM) has a Cash Flow Reinvestment Rate of 0.00x as of September 2023, reinvesting CA$0.00 (capex CA$0.00 ) from operating cash flow of CA$644.28K. See Big Pharma Split Corp Class A free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.00x
(Capex + Investments) / Operating CF

Total Reinvested

CA$0.00
Capex + Investments

Operating Cash Flow

CA$644.28K
CAD

Capital Expenditures

CA$0.00
CAD

Big Pharma Split Corp Class A Cash Flow Reinvestment Rate (2018–2023)

Historical reinvestment intensity for Big Pharma Split Corp Class A across 5 annual periods. For the full cash flow conversion analysis, see PRM operating cash flow.

Annual Cash Flow Reinvestment Rate for Big Pharma Split Corp Class A (2018–2023)

Year-by-year capital reinvestment analysis for Big Pharma Split Corp Class A. See financial flexibility index of Big Pharma Split Corp Class A to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (CAD) Operating CF Capex YoY Change
2023 0.00x CA$3.00 CA$11.86 Million CA$3.00
2022 0.00x CA$0.00 CA$1.13 Million CA$0.00 ▼ -100.0%
2020 0.00x CA$3.00 CA$4.35 Million CA$3.00
2019 0.00x CA$0.00 CA$8.68 Million CA$0.00
2018 0.00x CA$0.00 CA$1.27 Million CA$0.00
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow